Bibliography
- Lorenz W, Reimann HJ, Schmal A, Histamine release in dogs by Cremophor E1 and its derivatives: oxethylated oleic acid is the most effective constituent. Agents Actions 1977;7(1):63-7
- Weiss RB, Donehower RC, Wiernik PH, Hypersensitivity reactions from taxol. J Clin Oncol 1990;8(7):1263-8
- Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 2001;37(13):1590-8
- Ibrahim NK, Desai N, Legha S, Phase I and pharmacokinetic study of ABI-007, a cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 2002;8(5):1038-44
- Desai N, Trieu V, Yao Z, Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 2006;12(4):1317-24
- Blum JL, Savin MA, Edelman G, Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes. Clin Breast Cancer 2007;7(11):850-6
- Gardner ER, Dahut WL, Scripture CD, Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-Paclitaxel. Clin Cancer Res 2008;14(13):4200-5
- Nyman DW, Campbell KJ, Hersh E, Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J Clin Oncol 2005;23(31):7785-93
- Gradishar WJ, Tjulandin S, Davidson N, Phase III Trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005; 23(31):7794-803
- Rosenberg LJ. nab-Paclitaxel for treatment of solid tumors: beyond breast cancer. Commun Oncol 2008;5(6 Suppl 7):8-15
- Venook AP, Egorin MJ, Rosner GL, Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264. J Clin Oncol 1998;16(5):1811-9
- Monsarrat B, Alvinerie P, Wright M, Hepatic metabolism and biliary excretion of taxol in rats and human. J Natl Cancer Inst Monogr 1993;15:39-46
- Taxol (paclitaxel) injection: package insert. Bristol-Myers Squibb, Co., Princeton, NJ; 2003
- Eisenhauer EA, Therasse P, Bogaerts J, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45(2):228-47
- Sparreboom A, Scripture CD, Trieu V, Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in cremophor (taxol). Clin Cancer Res 2005;11(11):4136-43
- Joerger M, Huitema AD, Huizing MT, Safety and pharmacology of paclitaxel in patients with impaired liver function: a population pharmacokinetic-pharmacodynamic study. Br J Clin Pharmacol 2007;64(5):622-33
- Henningsson A, Sparreboom A, Sandstrom M, Population pharmacokinetic modelling of unbound and total plasma concentrations of paclitaxel in cancer patients. Eur J Cancer 2003;39(8):1105-14
- Donelli MG, Zucchetti M, Munzone E, Pharmacokinetics of anticancer agents in patients with impaired liver function. Eur J Cancer 1998;34(1):33-46
- Perry MC. Chemotherapeutic agents and hepatoxicity. Semin Oncol 1992;19:551-65
- Eklund J, Trifilio S, Mulcahy M. Chemotherapy dosing in the setting of liver dysfunction. Oncology 2005;19:1057-69
- Superfin D, Iannucci AA, Davies AM. Commentary: oncologic drugs inpatients with organ dysfunction: a summary. Oncologist 2007;12:1070-83